The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Using carfilzomib/dexamethasone for MM in the real world
Data from the ENDEAVOUR trial (NCT01568866) has shown that using carfilzomib plus dexamethasone (Kd) is more effective in treating relapsed/refractory multiple myeloma (MM) than the standard combination of bortezomib and dexamethasone (Vd). Here, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, speaking from the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, discusses using Kd therapy to treat patients outside of the clinical trial setting. He discusses ways to minimize risk, such as monitoring blood pressure rigorously and limiting fluid intake, as well as ways to manage long-term administration of Kd therapy.
